• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

分化剂丁酸盐在人前列腺癌细胞中对雄激素受体的非配体依赖性激活。

Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells.

作者信息

Sadar M D, Gleave M E

机构信息

Department of Cancer Endocrinology, British Columbia Cancer Agency, Vancouver, Canada.

出版信息

Cancer Res. 2000 Oct 15;60(20):5825-31.

PMID:11059779
Abstract

Androgens are potent differentiation agents that regulate prostate-specific antigen (PSA) gene expression via the androgen receptor (AR) that binds to androgen response elements (AREs) on the PSA gene to initiate transcription. However, in the absence of androgens, PSA gene expression can become elevated. This suggests that either the AR can be activated in the absence of androgen to elevate PSA gene expression through AREs on the PSA gene or that another transcription factor acting on the PSA promoter is stimulated. We have previously shown in vivo that butyrate, a differentiation agent that causes cell cycle arrest, increases serum PSA levels in castrated animals. Therefore, to determine the mechanism of butyrate induction of PSA, we used the LNCaP human prostate cancer cell line. Northern analyses and transfection experiments using a PSA reporter plasmid demonstrated induction of PSA gene expression by butyrate in LNCaP cells. Application of the antiandrogen bicalutamide blocked the induction of PSA mRNA by butyrate, suggesting a mechanism dependent on the AR. Consistent with this conclusion, electromobility shift assays showed increased AR-ARE complex formation with nuclear extracts from butyrate-treated cells. In addition, other reporter gene constructs that contain AREs were also induced by butyrate. Western blot analysis showed an increase in nuclear levels of AR protein in cells exposed to butyrate, whereas whole cell levels remained unchanged, suggesting that butyrate causes nuclear translocation of the AR. Thus, the differentiation agent butyrate causes ligand-independent activation of the AR to increase expression of the differentiation marker PSA in human prostate cancer cells.

摘要

雄激素是强效分化因子,可通过雄激素受体(AR)调节前列腺特异性抗原(PSA)基因的表达,该受体与PSA基因上的雄激素反应元件(ARE)结合以启动转录。然而,在没有雄激素的情况下,PSA基因表达可能会升高。这表明,要么AR可以在没有雄激素的情况下被激活,通过PSA基因上的ARE来提高PSA基因表达,要么作用于PSA启动子的另一种转录因子受到刺激。我们之前在体内研究中发现,丁酸盐作为一种导致细胞周期停滞的分化剂,可使去势动物的血清PSA水平升高。因此,为了确定丁酸盐诱导PSA的机制,我们使用了LNCaP人前列腺癌细胞系。Northern分析和使用PSA报告质粒的转染实验表明,丁酸盐可诱导LNCaP细胞中PSA基因的表达。抗雄激素药物比卡鲁胺的应用可阻断丁酸盐对PSA mRNA的诱导作用,提示其机制依赖于AR。与此结论一致,电泳迁移率变动分析显示,丁酸盐处理细胞的核提取物中AR-ARE复合物的形成增加。此外,其他含有ARE的报告基因构建体也被丁酸盐诱导。蛋白质印迹分析显示,暴露于丁酸盐的细胞中AR蛋白的核水平增加,而全细胞水平保持不变,这表明丁酸盐可导致AR的核转位。因此,分化剂丁酸盐可导致AR的非配体依赖性激活,从而增加人前列腺癌细胞中分化标志物PSA的表达。

相似文献

1
Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells.分化剂丁酸盐在人前列腺癌细胞中对雄激素受体的非配体依赖性激活。
Cancer Res. 2000 Oct 15;60(20):5825-31.
2
Down-Regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer.过氧化物酶体增殖物激活受体γ配体对人前列腺癌中前列腺特异性抗原表达的下调作用
Cancer Res. 2000 Oct 1;60(19):5494-8.
3
Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).鞘脂激活蛋白原上调前列腺癌细胞(LNCaP)中雄激素受体(AR)和前列腺特异性抗原(PSA)的表达及活性。
Prostate. 2007 Feb 1;67(2):178-89. doi: 10.1002/pros.20513.
4
Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor.胰岛素样生长因子-I、角质形成细胞生长因子和表皮生长因子对前列腺肿瘤细胞系中雄激素受体的激活作用。
Cancer Res. 1994 Oct 15;54(20):5474-8.
5
Regulation of FGF8 expression by the androgen receptor in human prostate cancer.雄激素受体对人前列腺癌中FGF8表达的调控
Oncogene. 2002 Aug 1;21(33):5069-80. doi: 10.1038/sj.onc.1205663.
6
Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.雄激素受体非基因组信号的变化与LNCaP细胞向雄激素非依赖性的转变相关。
Cancer Res. 2004 Oct 1;64(19):7156-68. doi: 10.1158/0008-5472.CAN-04-1121.
7
Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model.丁酸类似物异丁酰胺可抑制人前列腺LNCaP肿瘤模型中的肿瘤生长及雄激素非依赖性进展时间。
J Cell Biochem. 1998 Jun 1;69(3):271-81.
8
Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.在一个新的模型系统中,雄激素受体拮抗剂比卡鲁胺向激动剂的转变与前列腺肿瘤进展相关。
Br J Cancer. 1999 Sep;81(2):242-51. doi: 10.1038/sj.bjc.6690684.
9
Establishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10.建立并鉴定雄激素受体依赖性、雄激素非依赖性的人前列腺癌细胞系 LNCaP-CS10。
Prostate. 2010 Apr 1;70(5):457-66. doi: 10.1002/pros.21079.
10
Androgen receptor-mediated repression of novel target genes.雄激素受体介导的新型靶基因抑制作用。
Prostate. 2007 Sep 15;67(13):1371-83. doi: 10.1002/pros.20623.

引用本文的文献

1
Uncovering a novel mechanism: Butyrate induces estrogen receptor alpha activation independent of estrogen stimulation in MCF-7 breast cancer cells.揭示一种新机制:丁酸盐在MCF-7乳腺癌细胞中诱导雌激素受体α激活,且不依赖于雌激素刺激。
Genet Mol Biol. 2024 Mar 8;47(1):e20230110. doi: 10.1590/1678-4685-GMB-2023-0110. eCollection 2024.
2
hASH1 nuclear localization persists in neuroendocrine transdifferentiated prostate cancer cells, even upon reintroduction of androgen.组蛋白 HASH1 的核定位在神经内分泌转化的前列腺癌细胞中仍然存在,即使雄激素重新引入也是如此。
Sci Rep. 2019 Dec 13;9(1):19076. doi: 10.1038/s41598-019-55665-y.
3
Overexpression of Endothelial Cell-Specific Molecule 1 Correlates with Gleason Score and Expression of Androgen Receptor in Prostate Carcinoma.
内皮细胞特异性分子 1 的过表达与前列腺癌的 Gleason 评分和雄激素受体表达相关。
Int J Med Sci. 2017 Sep 30;14(12):1263-1267. doi: 10.7150/ijms.21023. eCollection 2017.
4
Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer.用于降解雄激素受体变体以治疗去势抵抗性前列腺癌的新型选择性药物。
Cancer Res. 2017 Nov 15;77(22):6282-6298. doi: 10.1158/0008-5472.CAN-17-0976. Epub 2017 Oct 4.
5
Androgen receptor variants occur frequently in castration resistant prostate cancer metastases.雄激素受体变异体在去势抵抗性前列腺癌转移中经常发生。
PLoS One. 2011;6(11):e27970. doi: 10.1371/journal.pone.0027970. Epub 2011 Nov 17.
6
Interleukin-6: a multifunctional targetable cytokine in human prostate cancer.白细胞介素-6:人类前列腺癌中一种具有多功能靶向性的细胞因子。
Mol Cell Endocrinol. 2012 Sep 5;360(1-2):52-8. doi: 10.1016/j.mce.2011.05.033. Epub 2011 Jun 1.
7
Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.在人类前列腺癌中,雄激素受体剪接变体的频繁发生导致去势抵抗。
J Clin Invest. 2010 Aug;120(8):2715-30. doi: 10.1172/JCI41824. Epub 2010 Jul 19.
8
Androgen-responsive gene database: integrated knowledge on androgen-responsive genes.雄激素应答基因数据库:关于雄激素应答基因的综合知识
Mol Endocrinol. 2009 Nov;23(11):1927-33. doi: 10.1210/me.2009-0103. Epub 2009 Sep 17.
9
Histone deacetylase inhibitors: the anticancer, antimetastatic and antiangiogenic activities of AN-7 are superior to those of the clinically tested AN-9 (Pivanex).组蛋白去乙酰化酶抑制剂:AN-7的抗癌、抗转移和抗血管生成活性优于经临床测试的AN-9(匹伐他汀)。
Clin Exp Metastasis. 2008;25(7):703-16. doi: 10.1007/s10585-008-9179-x. Epub 2008 May 28.
10
Basic science of hormonal therapy for prostate cancer.前列腺癌激素治疗的基础科学
Rev Urol. 2001;3 Suppl 3(Suppl 3):S15-22.